Payment overview · 2025
General Payments
$414.54
12 reported records · 8 companies
Healthcare provider profile · identity verified
Marlene E Mires, MD
Allopathic & Osteopathic Physicians|Family Medicine · BREA, CA · NPI 1235185976
Verified facts
What the public records show
CMS Open Payments records show Marlene E Mires, MD received $414.54 in general payments during 2025 across 12 reported records.
Nova Eye, Inc. accounted for 30.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Mounjaro by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Nova Eye, Inc. | Unresolved — no canonical attribution shown | $125.00 | 30.1% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $93.38 | 22.5% | 3 | 2025 |
| MAYNE PHARMA COMMERCIAL LLC | Unresolved — no canonical attribution shown | $64.76 | 15.6% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $49.78 | 12.0% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $21.80 | 5.3% | 1 | 2025 |
| Intra-Sana Laboratories | Unresolved — no canonical attribution shown | $21.39 | 5.2% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $20.57 | 5.0% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.86 | 4.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $414.54 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $93.38 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $93.38 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $49.78 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $49.78 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $21.80 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $21.80 | 1 | 2025 |
Source payment records
|
|||||
| GLYCATE Normalized: glycate |
Drug | Intra-Sana Laboratories | $21.39 | 1 | 2025 |
Source payment records
|
|||||
| RELTONE 200 MG Normalized: reltone 200 mg |
Drug | Intra-Sana Laboratories | $21.39 | 1 | 2025 |
Source payment records
|
|||||
| RELTONE 400 MG Normalized: reltone 400 mg |
Drug | Intra-Sana Laboratories | $21.39 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $20.57 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $17.86 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
53 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 668 | 197 |
| Atorvastatin Calcium | Atorvastatin Calcium | 649 | 210 |
| Levothyroxine Sodium | Levothyroxine Sodium | 430 | 124 |
| Lisinopril | Lisinopril | 337 | 105 |
| Losartan Potassium | Losartan Potassium | 320 | 109 |
| Metformin Hcl | Metformin Hcl | 280 | 90 |
| Pantoprazole Sodium | Pantoprazole Sodium | 247 | 78 |
| Alendronate Sodium | Alendronate Sodium | 231 | 71 |
| Simvastatin | Simvastatin | 218 | 67 |
| Omeprazole | Omeprazole | 204 | 68 |
| Escitalopram Oxalate | Escitalopram Oxalate | 183 | 54 |
| Metoprolol Succinate | Metoprolol Succinate | 182 | 58 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 154 | 44 |
| Lovastatin | Lovastatin | 139 | 42 |
| Ezetimibe | Ezetimibe | 135 | 43 |
| Fluticasone Propionate | Fluticasone Propionate | 123 | 49 |
| Gabapentin | Gabapentin | 120 | 44 |
| Trazodone Hcl | Trazodone Hcl | 105 | 34 |
| Hydrochlorothiazide | Hydrochlorothiazide | 103 | 31 |
| Atenolol | Atenolol | 102 | 31 |
| Ozempic | Semaglutide | 98 | 20 |
| Potassium Chloride | Potassium Chloride | 97 | 36 |
| Metoprolol Tartrate | Metoprolol Tartrate | 96 | 29 |
| Valsartan | Valsartan | 87 | 25 |
| Tamsulosin Hcl | Tamsulosin Hcl | 86 | 29 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 84 | 38 |
| Pravastatin Sodium | Pravastatin Sodium | 83 | 29 |
| Benazepril Hcl | Benazepril Hcl | 78 | 24 |
| Citalopram Hbr | Citalopram Hydrobromide | 78 | 24 |
| Zolpidem Tartrate | Zolpidem Tartrate | 77 | 11 |
| Furosemide | Furosemide | 74 | 29 |
| Hydralazine Hcl | Hydralazine Hcl | 71 | 23 |
| Famotidine | Famotidine | 70 | 26 |
| Pioglitazone Hcl | Pioglitazone Hcl | 70 | 26 |
| Synthroid | Levothyroxine Sodium | 70 | 18 |
| Alprazolam | Alprazolam | 69 | 29 |
| Montelukast Sodium | Montelukast Sodium | 68 | 19 |
| Azelastine Hcl | Azelastine Hcl | 67 | 26 |
| Allopurinol | Allopurinol | 66 | 17 |
| Januvia | Sitagliptin Phosphate | 64 | 19 |
| Sertraline Hcl | Sertraline Hcl | 64 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 62 | 19 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 59 | 35 |
| Donepezil Hcl | Donepezil Hcl | 54 | 12 |
| Carvedilol | Carvedilol | 53 | 13 |
| Eliquis | Apixaban | 53 | suppressed |
| Meloxicam | Meloxicam | 50 | 18 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 48 | 14 |
| Bupropion Xl | Bupropion Hcl | 45 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 45 | 12 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 45 | 12 |
| Celecoxib | Celecoxib | 44 | 20 |
| Clonidine Hcl | Clonidine Hcl | 43 | 12 |
| Azithromycin | Azithromycin | 41 | 38 |
| Lorazepam | Lorazepam | 41 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 40 | 13 |
| Spironolactone | Spironolactone | 38 | 12 |
| Nystatin | Nystatin | 36 | 14 |
| Estradiol | Estradiol | 34 | suppressed |
| Memantine Hcl | Memantine Hcl | 34 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 34 | 12 |
| Mirtazapine | Mirtazapine | 34 | suppressed |
| Glipizide | Glipizide | 33 | suppressed |
| Temazepam | Temazepam | 33 | suppressed |
| Tradjenta | Linagliptin | 33 | suppressed |
| Glimepiride | Glimepiride | 30 | suppressed |
| Ondansetron Odt | Ondansetron | 30 | 14 |
| Ibuprofen | Ibuprofen | 29 | 16 |
| Jardiance | Empagliflozin | 28 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 27 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 26 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 26 | 14 |
| Sumatriptan Succinate | Sumatriptan Succinate | 26 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 25 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 25 | suppressed |
| Premarin | Estrogens, Conjugated | 24 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 23 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 22 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 21 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 21 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 20 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Chlorthalidone | Chlorthalidone | 18 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 18 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Lansoprazole | Lansoprazole | 17 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 17 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Mounjaro | Tirzepatide | 16 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 16 | 15 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 15 | 12 |
| Enalapril Maleate | Enalapril Maleate | 15 | suppressed |
| Sucralfate | Sucralfate | 15 | suppressed |
| Ciclopirox | Ciclopirox | 14 | suppressed |
| Eszopiclone | Eszopiclone | 14 | suppressed |
| Finasteride | Finasteride | 14 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 14 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Cefdinir | Cefdinir | 13 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 13 | suppressed |
| Febuxostat | Febuxostat | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | 12 |
| Clonazepam | Clonazepam | 12 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Etodolac | Etodolac | 12 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | 11 |
| Acyclovir | Acyclovir | 11 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 11 | suppressed |
| Klor-Con 10 | Potassium Chloride | 11 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Rybelsus | Semaglutide | 11 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $414.54 · 12 records | Nova Eye, Inc. | COMIRNATY, FARXIGA, GLYCATE, JARDIANCE, MOUNJARO, OTEZLA, PREVNAR 20, RELTONE 200 MG, RELTONE 400 MG, REPATHA, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error